ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 31 filers reported holding ASCENDIS PHARMA A/S in Q4 2016. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $11,614,714 | -8.0% | 108,326 | +4.7% | 0.02% | -10.7% |
Q4 2022 | $12,631,417 | -52.7% | 103,426 | -60.0% | 0.03% | -52.5% |
Q3 2022 | $26,731,000 | +331.0% | 258,875 | +288.0% | 0.06% | +353.8% |
Q2 2022 | $6,202,000 | -68.9% | 66,716 | -60.7% | 0.01% | -65.8% |
Q1 2022 | $19,941,000 | -42.6% | 169,911 | -34.2% | 0.04% | -40.6% |
Q4 2021 | $34,718,000 | +1517.8% | 258,070 | +1816.6% | 0.06% | +611.1% |
Q3 2021 | $2,146,000 | -10.3% | 13,465 | -36.6% | 0.01% | -62.5% |
Q1 2020 | $2,393,000 | +789.6% | 21,246 | +998.0% | 0.02% | +1100.0% |
Q4 2019 | $269,000 | +2.3% | 1,935 | -29.3% | 0.00% | 0.0% |
Q3 2019 | $263,000 | -96.1% | 2,737 | -95.3% | 0.00% | -93.8% |
Q1 2019 | $6,814,000 | +503.5% | 57,896 | +221.2% | 0.03% | +166.7% |
Q4 2018 | $1,129,000 | +27.7% | 18,027 | +44.5% | 0.01% | +200.0% |
Q3 2018 | $884,000 | +13.0% | 12,476 | +6.1% | 0.00% | -66.7% |
Q2 2018 | $782,000 | -2.1% | 11,758 | -3.8% | 0.01% | -63.6% |
Q1 2018 | $799,000 | -54.9% | 12,218 | -86.0% | 0.03% | +175.0% |
Q4 2016 | $1,772,000 | – | 87,558 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |